p16基因在肺癌中突变和表达改变的研究  

The mutation and down-expression of p16 gene in human lung cancer

作　　者：曾庆彪[1] 吴立平[1] 谢金魁[1] 彭燕玲[1] 

机构地区：[1]衡阳医学院第一附属医院病理科,421001

出　　处：《肿瘤防治研究》2002年第1期27-29,共3页Cancer Research on Prevention and Treatment

摘　　要：目的 检测非小细胞肺癌ｐ１６ 基因蛋白表达及其第 ２外显子突变，并探讨其与非小细胞肺癌的临床病理类型和预后的关系。方法 用Ｓ－Ｐ免疫组化法对ｐ１６基因蛋白表达进行对比检测，并用 ＰＣＲ－ＳＳＣＰ银染技术检测ｐ１６基因第 ２外显子的突变情况。结果 非小细胞肺癌中 ｐ１６蛋白表达阳性率５２．５％，肺部非癌性病变阳性率９２．５％，两者比较差异有显著性意义（Ｐ＜０．０５）；非小细胞肺癌中 Ｐ１６基因第 ２外显子突变率为 ５％，而肺部非癌性病变中无一例突变。结论 ｐ１６蛋白表达下调在非小细胞肺癌的发生发展中起重要作用，对判断其预后有意义，提示 Ｐ１６／ＭＴＳ１基因在非小细胞肺癌发生中具有一定的作用。Objective To detect pl6 gene mutation and expression in human non-small cell lung cancer (NSCLS), and to study the relationship between p16 expression and clinicpathologic features and progno- sis. Methods With S-P immunohistochenistry method, we investigated piG protein expression. Mutation in exon 2 of p16/MTSJ gene was screened by PCR-SSCP analyzing with non-isotope silve staining method. Results The positive rate of piG expression in NSCLC and lung benigh diseases was 52. 5% and 92. 50% ,re- spectively(P<0. 05). Mutation in exon 2 of p16 gene were found in 5%(2/40) and no mutation was found in 40 cases of lung benigh disease. Conclusion p16/MTSI expression down-regulation may play an impor- tant role in tumor development of NSCLC. p16/MTSL gene could play a certain role in development of NSCLC.

关 键 词：肺癌 基因突变 蛋白表达 P16基因 免疫组化 

分 类 号：R734.2[医药卫生—肿瘤]